A Prospective, Open-Labeled Trial of the Safety and Efficacy of Doxazosin GITS in Patients With Benign Prostate Hyperplasia

NCT00648323 Phase 4 COMPLETED

The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.

Details

Lead sponsor	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase	Phase 4
Status	COMPLETED
Enrolment	80
Start date	2003-11
Completion	2005-01

Conditions

• Prostate

Interventions

• Doxazosin mysylate GITS

Primary outcomes

• Change in the maximum urinary flow rate (Qmax) from baseline — 8 weeks
• Change in the International Prostate Symptom Score (IPSS) total score from baseline — 8 weeks

Countries

Taiwan